CA-GLOBALLOGIC
4.8.2022 05:32:14 CEST | Business Wire | Press release
GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that its President and CEO Shashank Samant will be succeeded by the firm’s current Chief Operating Officer (COO) Nitesh Banga, who will become the new President and CEO effective October 1, 2022. Nitesh is a well-rounded and seasoned executive who has successfully worked across functions from Strategy, Go-To-Market, Engineering, and Operations while also launching similar businesses in the Japan market. Shashank will assume a new role as Chairman of the GlobalLogic Board, in addition to being the Executive Advisor to Mr. Toshiaki Tokunaga, the Head of Hitachi Digital Systems and Services (DSS) Sector. In this capacity, Shashank will continue to support the GlobalLogic business as well as advise on Hitachi Group's broader digital business growth strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803006014/en/
For more than a decade as CEO, Shashank led GlobalLogic through strong growth phases during which he oversaw several strategic acquisitions and digital capability expansion efforts. His leadership and expertise took the company from a group of elite software engineers to a global digital engineering leader, eventually becoming a part of the Hitachi Group.
“I am proud of the industry leading growth we achieved during my time as GlobalLogic’s CEO,” commented Shashank. “I believe that for organizations to continue to lead and succeed, their executive leadership must also evolve. Nitesh has proven throughout his career that he is a strong leader across both vision and execution. I am confident that he will set a successful course that will take GlobalLogic through its next major growth phases. I’m also very excited to continue supporting GlobalLogic in my new role as Chairman of the Board as well as to contribute to Hitachi Group’s digital business expansion and digital transformation acceleration.”
Since his arrival in 2018, Nitesh has led critical functions of GlobalLogic’s business. He contributed significantly to GlobalLogic’s noteworthy growth while also adeptly navigating the company through monumental challenges including the COVID-19 pandemic and the war in Ukraine.
Nitesh is a services industry veteran with diversified expertise ranging across Strategy, Business Development, Service Delivery, Operations, and Mergers and Acquisitions. He has adeptly run large-scale P&L organizations and has a deep understanding of Western and Eastern cultures, including Japan. Prior to joining GlobalLogic, he spent more than two decades at IT services and consulting firm Infosys.
“It’s an honor and great responsibility to lead GlobalLogic,” said Nitesh. “The passion, expertise, and deep commitment to our clients’ success demonstrated by our employees has created an invigorating, creative institution. As we enter our third decade, we have a unique opportunity to accelerate enterprise digital transformation backed by Hitachi’s incredible heritage, global reach, and trusted brand.”
“Since GlobalLogic joined the Hitachi Group, Shashank has made significant contributions to the growth of its entire digital business. I look forward to his continued strength in helping the Hitachi Group grow and transform through digital technology,” said Keiji Kojima, President and CEO of Hitachi, Ltd. "Nitesh has had an excellent track record as COO of GlobalLogic and I am confident that he will be able to maintain the high momentum of growth in the future. We are pleased to be working with a leader of his caliber to deliver new value through innovation, Green, and Digital solutions for our customers around the world."
“With GlobalLogic becoming a part of the Hitachi Family, Hitachi’s digital capability has expanded tremendously,” said Mr. Tokunaga. “I would like to thank Shashank for his capable leadership and look forward to his contributions as Chairman of the Board. Going forward, under Nitesh's leadership, I expect GlobalLogic to continue creating synergies with Hitachi Digital and other Hitachi Group companies, and to dramatically expand the digital business through DX support for customers worldwide.”
About GlobalLogic Inc.
GlobalLogic (www.globallogic.com
) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd.
(TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
About Hitachi, Ltd.
Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company’s consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com
.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803006014/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom